HW
ANIP icon

Hancock Whitney’s ANI Pharmaceuticals ANIP Stock Holding History

Hancock Whitney’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$292K Buy
+3,523
New +$283K ﹤0.01% 677
2024
Q4 		– Sell
-5,299
Closed -$316K – 634
2024
Q3 		$316K Buy
5,299
+80
+2% +$4.88K 0.01% 525
2024
Q2 		$332K Buy
5,219
+7
+0.1% +$454 0.01% 494
2024
Q1 		$360K Buy
+5,212
New +$315K 0.01% 507
2020
Q2 		– Sell
-8,083
Closed -$329K – 785
2020
Q1 		$329K Buy
8,083
+1,955
+32% +$104K 0.01% 604
2019
Q4 		$378K Sell
6,128
-3,918
-39% -$260K 0.01% 620
2019
Q3 		$732K Sell
10,046
-1,400
-12% -$105K 0.02% 506
2019
Q2 		$941K Buy
11,446
+155
+1% +$11K 0.03% 470
2019
Q1 		$796K Buy
11,291
+2,400
+27% +$141K 0.03% 519
2018
Q4 		$401K Sell
8,891
-2,179
-20% -$114K 0.01% 649
2018
Q3 		$626K Sell
11,070
-1,142
-9% -$69.9K 0.02% 596
2018
Q2 		$816K Buy
+12,212
New +$762K 0.04% 373

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hancock Whitney's ANIP Position: Q2 2026 in Review

Hancock Whitney opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 3,523 shares worth $292K. The stake represents ﹤0.01% of the portfolio and ranks #677 among its holdings. This is a return to the name: Hancock Whitney previously reported a position in ANIP as recently as Q3 2024.

Hancock Whitney first reported a position in ANIP in Q2 2018 and has held it in 12 quarters since. The position peaked at $941K in Q2 2019. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Hancock Whitney held 3,523 shares of ANI Pharmaceuticals worth $292K as of Q2 2026.
  • ANI Pharmaceuticals was a new Hancock Whitney position in Q2 2026.
  • ANI Pharmaceuticals made up ﹤0.01% of Hancock Whitney's portfolio in Q2 2026, its #677 holding.
  • Hancock Whitney first reported a position in ANI Pharmaceuticals in Q2 2018 and has held it in 12 quarters since.
  • Hancock Whitney's ANI Pharmaceuticals position peaked at $941K in Q2 2019.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Hancock Whitney's 13F filing for Q2 2026, filed 14 Aug 2026.